Title of article :
Myeloprolipherative Disorder Type Chronic Myeloid Leucemia - Eosinophilic Form
Author/Authors :
Aida Arnautovic-Custovic، نويسنده , , Samira Hasic، نويسنده , , Emina Kopic، نويسنده , , Azra Jahic، نويسنده , , Svetlana Jovic، نويسنده ,
Issue Information :
دوماهنامه با شماره پیاپی سال 2011
Abstract :
Chronic eosinophilic leucemia (CEL) is a very rare form of leucemia in the western world. Adequate response is seldomly achieved after treatment with corticosteroids, interferon-alfa (INF-alfa) and medications containing hydroxi-urea (Litalir). The study presents a patient with CEL with no initial therapeutic response to the use of corticosteroids, INF-alfa and hydroxi-urea, and with neither clinical nor hematological response. After setting a diagnosis of CEL, patient was ordinated Imatinib (Glivec tabbletes) in a daily dose of 200 mg. Two days afterwards there was an evident withdrawal of subjective and clinical symptoms of disease, and the complete blood count showed significant amendment.
Keywords :
chronic eosinophilic leucemia , imatinib (GlEEVEC)
Journal title :
Medical Archives
Journal title :
Medical Archives